Tau Global Conference 2025 maps new routes to understanding and treating tauopathies
Experts report advances in tau degradation, brain spread, human cell models, sleep and social risk factors, pointing toward biomarker-guided, global tauopathy research.
Resumen
The Tau Global Conference 2025 in London merged three major tau meetings. Researchers from academia, industry, government and philanthropy reviewed progress in tauopathies such as Alzheimer's disease, PSP, CBD and frontotemporal dementia. Key themes included lysosomal enzymes that break down tau, and mutations that may slow that clearance. Tau also appears to spread along brain networks, with amyloid-β and microglia accelerating it. New models, including directly reprogrammed human neurons, knock-in mice and live human brain slices, are sharpening mechanistic work. Risk modifiers discussed included socioeconomic deprivation, sleep disruption and endemic parkinsonism clusters. The report stresses biomarker-informed trials and global, inclusive collaboration. It is a conference summary, not a primary study, so findings are preliminary and vary in evidence strength.
Resumen detallado
Tauopathies are a diverse group of neurodegenerative diseases. Primary forms include progressive supranuclear palsy (PSP), corticobasal degeneration and Pick's disease. In secondary forms such as Alzheimer's disease (AD), tau abnormalities occur alongside other pathology. Progress has been slowed by tau's molecular complexity, clinical heterogeneity, the lack of early biomarkers and poor translation from preclinical work. This report summarizes the Tau Global Conference 2025, held in London and online in April 2025. It merged Global Tau, EuroTau and CurePSP Neuro, and included people living with tauopathies and their care partners.
The report is a narrative synthesis of presentations, not a systematic review or new trial. On tau biology, lysosomal cathepsins cleave tau in a selective, pH-dependent way. Many MAPT mutations reduce or abolish cleavage at specific sites and prolong the half-life of mutant tau (K257T, N279K, S305N) in cells and iPSC-derived neurons. The proline-rich domain resists cleavage, and phosphorylation at threonines 181 and 217 increases that resistance. This may help explain why p-tau181 and p-tau217 persist as fluid AD biomarkers, although this is speculative.
Tau-PET combined with connectivity data shows tau spreading preferentially along brain networks in AD, and similar patterns appear in 4R tauopathies such as PSP. Spread is faster when epicenters lie in highly connected hubs. Amyloid-β appears to induce neuronal hyperactivity that promotes tau release and spread. Post-mortem work implicates microglia, astrocytes and CD8+ T cells, and amyloid clearance after immunization was linked to restored microglial homeostasis and less tau pathology. A modeling study suggested that where tau accumulates depends mainly on connectivity and neuroreceptor distribution, whereas regional load depends on local factors such as MAPT expression, amyloid and blood flow.
New platforms included iPSC-derived vascular models, which reproduce APOE4-linked fibronectin (FN1) elevation. Directly reprogrammed neurons retain aging signatures and express all six tau isoforms at a physiological 3R:4R ratio. Humanized MAPT knock-in mice show synapse loss and cognitive decline without detectable tau aggregates. Live human brain slice cultures retained cell types for at least 7 days and took up PSP-derived tau, with astrogliosis and synapse engulfment. Risk-modifier data showed deprivation was associated with earlier institutionalization, not shorter survival, in FTLD syndromes (PiPPIN, UK). P301S mice showed sleep EEG changes early, and a dual orexin receptor antagonist improved sleep measures. Clusters of endemic parkinsonism implicate both environmental and genetic causes.
Implications are a push toward biomarker-guided, precision trials, human-relevant models and global collaboration to reduce research inequities. Caveats are that much evidence comes from mouse, in vitro or small post-mortem studies. Several mechanisms are hypotheses, and the available text was truncated before the genetics, biomarker and therapeutics sections.
Hallazgos clave
- Many MAPT mutations impair lysosomal cathepsin cleavage of tau, prolonging mutant tau half-life in cells and iPSC-derived neurons.
- Tau spreads along connected brain networks in AD and PSP, accelerating when epicenters sit in highly connected hub regions.
- Where tau accumulates tracks connectivity and neuroreceptors; regional tau load depends more on MAPT expression, amyloid and blood flow.
- In the UK PiPPIN study, deprivation did not shorten survival in FTLD syndromes but predicted earlier institutional care.
- Young PS19 tau mice show sleep spindle deficits, and a dual orexin antagonist improved sleep and REM-without-atonia measures.
Metodología
This is a narrative conference report synthesizing presentations from the Tau Global Conference 2025 (London and online, April 2025). It draws on cited human imaging, post-mortem, epidemiological, animal and cell-model studies, and includes no new primary analysis. The provided text was truncated partway through the genetics section.
Limitaciones del estudio
As a conference summary, it relies on heterogeneous evidence, much of it from mice, iPSC cells and small human cohorts, and several proposals are speculative. Findings such as the deprivation result need replication in other health systems, and the available text omits the later biomarker and therapeutic sections.
¿Te ha gustado este resumen?
Recibe la última investigación sobre longevidad en tu bandeja de entrada cada semana.
Introduce tu correo electrónico para suscribirte: